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Veno-occlusive disease (VOD) of the liver is a well-recognized serious complication of hematopoietic stem
cell transplantation (HSCT), with few successful treatment modalities available for severe disease. Some
reports have demonstrated success in adults with the use of high-dose steroid therapy, but experience in the
pediatric population is lacking. We retrospectively reviewed HSCT patients treated at our institution since
2003 and identiﬁed 15 (2.4%) who developed VOD. Of these, nine (60%) were treated with intravenous high-
dose methylprednisolone (500 mg/m2 per dose every 12 hours for six doses). Steroid therapy was initiated at
or before ﬁrst ultrasound evidence of reversal of portal venous ﬂow and before meeting criteria for initiation
of deﬁbrotide therapy. Four patients were also treated with deﬁbrotide starting 2 to 5 days after initiation of
steroids. Eight of nine patients (88%) with VOD were diagnosed with multiorgan failure. Response to high-
dose steroid therapy as deﬁned by decrease in bilirubin by 50% in 10 days from therapy initiation was
noted in six of nine patients (67%), occurring within 3 to 6 days of steroid therapy. Two patients died from
multiorgan failure due to VOD. Seven survivors of VOD recovered at the median 6 days (range, 5 to 38) from
VOD diagnosis. Overall, VOD survival as a group was 78%; however, survival among responders was 100%. No
serious toxicities related to high-dose steroid therapy were observed. We conclude that high-dose steroid
therapy if initiated early may reverse VOD of the liver in pediatric HSCT patients, abrogating the need for
deﬁbrotide therapy with its associated toxicities and regulatory difﬁculties.
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Veno-occlusive disease (VOD) is a syndrome character-
ized by the clinical ﬁndings of ascites, rapid weight gain,
painful hepatomegaly, and jaundice and is a serious
complication of hematopoietic stem cell transplantation
(HSCT) [1,2]. VOD is a result of injury to sinusoidal endo-
thelial cells in zone 3 of the hepatic acinus [3,4]. It is more
common after allogeneic than after autologous HSCT, with
the most common precipitating event being the adminis-
tration of chemotherapy and radiation as part of preparative
therapy for HSCT. VOD has been reported in up to 55% of
patients after HSCT, with incidence varying widely depend-
ing on the type of transplant, preparative regimen, and
criteria used to make the diagnosis [1]. VOD is typically
diagnosed clinically based on either the Baltimore criteria of
hyperbilirubinemia (total serum bilirubin >2 mg/dL), weight
gain or ascites >5% over baseline, and tender hepatomegaly
or right upper quadrant pain of liver origin or the Seattle
criteria, which require two of the aforementioned criteria
before day þ20 [5]. Patients that do not meet all these
criteria are classiﬁed with liver dysfunction of uncertain
etiology. The clinical presentation of VOD ranges from mild,
reversible disease to a much more severe syndrome. Severeedgments on page 503.
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12.11.011multiorgan failure (MOF) and death. Very few successful
treatment modalities exist for severe disease.
Severe VOD is associated with a high mortality rate,
approaching 100% by day þ100 post-HSCT [2]. Current
standard treatments for VOD consist of supportive measures,
including analgesia, diuresis, transfusional and ventilatory
support, and renal replacement therapy [6]. Therapeutic
options targeting the underlying etiology, which remains
poorly understood, are few. Although deﬁbrotide, an alter-
native potential therapeutic option, is now more available,
signiﬁcant barriers to obtaining this therapy still remain for
many centers. In this retrospective report, we describe our
institutional experience with the treatment of VOD with
high-dose steroid therapy in pediatric HSCT patients.METHODS
The study was an institutional review boardeapproved retrospective
review of clinical data of HSCT patients at Cincinnati Children’s Hospital
Medical Center from January 1, 2003 until December 30, 2011. All patients
with diagnosis of VOD were identiﬁed, and medical charts were reviewed
and data abstracted, including patient demographics, transplant and clinical
data, laboratory and radiologic diagnostic studies, therapy, and overall
outcomes and related complications. VOD of the liver was deﬁned as bili-
rubin elevation of 2.0 mg/dL and at least two of the following symptoms:
ascites, weight gain 5% above pretransplant baseline weight, and hepa-
tomegaly increased above baseline. Ultrasound evaluation for evidence of
reversal of portal venous ﬂow was done but not required for diagnosis [7].
A diagnosis of severe VOD with MOF (VOD þ MOF) was made by the
presence of respiratory, renal, or both organ dysfunction in addition to VOD
criteria. Renal dysfunction was diagnosed in patients with serum creatinine
elevation at least three times pretransplant value, glomerular ﬁltration
40% of pretransplant value, or requirement for renal replacement therapy
attributed to VOD. Pulmonary dysfunction was diagnosed in patients with
oxygen saturation <90% on room air (two consecutive measurements at
least 1 hour apart) or requirement for oxygen supplementation/ventilator
Table 1
Patient and HSCT Characteristics
Patient Diagnosis Gender Age (yr) Donor Match Preparative regimen GVHD Prophylaxis
1 Pleuropulmonary blastoma Female 7 Auto Bu-Mel-thiotepa N/A
2 Chronic granulomatous Disease Male 10.6 MUD 7/8 Bu-Cy-ATG CSA/Pred
3 Retinoblastoma Male .7 Auto Carbo-VP16 thiotepa N/A
4 ALL Male 16.2 MSD 8/8 Cy-TBI CSA/Mtx
5 Fanconi anemia Female 6.3 MUD 8/8 Bu-Cy-Flu ATG CSA
6 Neuroblastoma Female 6.3 Auto Cy-thiotepa N/A
7 Neuroblastoma Male 2.8 Auto Carbo-VP16 Mel N/A
8 ALL Male 4.8 MUD 8/8 Cy-thiotepa TBI Siro/Tacro
9 Dyskeratosis congenita Male 1.2 MSD 8/8 Campath-Flu-Mel CSA/Pred
MSD indicates matched sibling donor; Auto, autologous stem cell transplant; ALL, acute lymphoblastic leukemia; MUD, matched unrelated donor; Bu, busulfan;
Mel, melphalan; Cy, cyclophosphamide; ATG, antithymocyte globulin; Carbo, carboplatin; VP16, etoposide; TBI, total body irradiation; Flu, ﬂudarabine; N/A, not
applicable; CSA, cyclosporin; Pred, prednisone; Mtx, methotrexate; Siro, sirolimus; Tacro, tacrolimus.
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abdominal distention or hepatic enlargement and not due to other causes
like an infection.
Steroid Therapy
High-dose steroid therapy consisted of intravenous methylprednisolone
500 mg/m2 per dose every 12 hours for six doses, followed by a taper to
2 mg/kg/day for 3 days, and subsequently tapered per treating physician
preference [8]. Steroid therapy was initiated at or before ﬁrst ultrasound
evidence of reversal of portal venous ﬂow and before enrollment on
compassionate-use study and initiation of deﬁbrotide therapy.
Deﬁbrotide Therapy
All patients receiving deﬁbrotide were enrolled in an institutional
review boardeapproved compassionate-use study and were monitored and
treated according to the protocol guidelines.
VOD Response Criteria
Response to high-dose steroid therapy was deﬁned per previously
published criteria [9] as a decrease in serum bilirubin by 50% or normali-
zation of bilirubin by 10 days from steroid therapy initiation. Completed
resolution of VOD was deﬁned as decline of bilirubin <2 mg/dL or
normalization of bilirubin for patients with reversal of ﬂow without bili-
rubin >2 mg/dL and resolution of MOF. Resolution of renal dysfunction was
deﬁned as serum creatinine <1.5 times from pretransplant value or
glomerular ﬁltration rate >80% of pretransplant value and renal replace-
ment therapy independent. Resolution of pulmonary dysfunction was
deﬁned as resolution of oxygen requirement with documentation of oxygen
saturation >90% on room air for at least 24 hours.
Patient Monitoring
All HSCT patients had uniform monitoring and prophylactic and
supportive care. Patients with suspected or diagnosed VOD had total and
direct bilirubin, blood urea nitrogen and serum creatinine, complete blood
count, platelets, ﬁbrinogen, prothrombin time, and partial thromboplastin
time checked daily. Liver Doppler sonography to evaluate for a reversal of
the blood ﬂow in the portal system or other pathology was performed at
attending physician discretion. HSCT patients requiring intensive care unit
admissions were cared for by both Critical Care and Bone Marrow Trans-
plantation teams. Patients on high-dose steroid therapy were closely
monitored for hypertension, hyperglycemia, mental status and mood
alteration, and infections, speciﬁcally viral and fungal infections.
Statistical Analysis
Data were managed and analyzed using R (version 2.15). Group differ-
ences were tested at 180 days post-HSCT (time of last follow-up) using
unconditional exact test.
RESULTS
Patient Characteristics
From 614 consecutive HSCT patients treated at our insti-
tution since 2003, we retrospectively identiﬁed 15 individ-
uals (2.4%) who developed severe VOD. Of these 15 patients,
9 (60%) were treated with high-dose methylprednisolone.
Patient demographic and transplant characteristics are
shown in Table 1. Median patient age was 6.3 years (range,
.7 to 16.2), andmost patients weremale (n¼ 6). Five patientsreceived allogeneic HSCT and four, autologous. One patient
with dyskeratosis congenita received reduced-intensity
conditioning, and all other patients received myeloablative
conditioning. VOD was diagnosed before day þ21 of trans-
plantation in all patients, with the exception of one patient
who had late VOD presentation at day þ31 after initial
successful discharge from the transplant unit.
Eight of nine patients (89%) had MOF at diagnosis of VOD
when steroid therapy was initiated (Table 2). Four of these
eight patients (50%) required renal replacement therapy,
whereas ﬁve (63%) required ventilator support. Two patients
had hepatic encephalopathy and received therapeutic
plasma exchange with resolution of neurologic symptoms.
Four of nine patients (44%) were also treatedwith deﬁbrotide
starting 1 to 5 days after initiation of high-dose steroids.
There was no other VOD-directed therapy besides high-dose
steroids, deﬁbrotide, and supportive care.
Treatment Response and Outcome
Six patients (67%) had documented response to steroid
therapy by 50% decrease in bilirubin in 10 days from initia-
tion of therapy (median, 4 days; range, 3 to 6). Four patients
receiving deﬁbrotide initiated therapy within 1 to 5 days of
steroid initiation as shown inTable 2. Twopatients (22%) died
due to VOD þ MOF. Seven survivors (78%) of VOD recovered
completely at a median of 6 days (range, 5 to 38) from
diagnosis and were alive and well at a median of 766 days
(range, 183 to 1624) post-transplant. Overall, VOD survival as
a group was 78%; however, survival among all responders
was 100%. Comparison of overall survival at 180 days (time of
last follow-up) between responders and nonresponders was
100% versus 33%, respectively (P ¼ .0374).
Five patients received steroids alone, four of which also
had MOF at diagnosis of VOD when steroid therapy was
initiated (Table 2). All ﬁve patients responded to steroid
therapy with complete resolution of VOD.
Complications of High-Dose Steroid Therapy
No serious toxicities related to high-dose steroid therapy,
such as refractory hypertension or hyperglycemia, increased
infection, or behavioral disturbances, were observed. Tran-
sient moderate hypertension was seen in four patients and
transient hyperglycemia in four patients. Two patients with
VOD þ MOF treated with steroids and deﬁbrotide had life-
threatening pulmonary hemorrhages attributed to deﬁbro-
tide and did not survive.
DISCUSSION
Optimal disease-targeted treatment strategies for severe
VOD in pediatric patients have yet to be determined.
Table 2
VOD Disease Characteristics and Outcome
Patient Diagnosis Doppler of Portal
System (Day)
Days
from
BMT
to VOD
Therapy
(Day
Initiated)
Maximum
Bilirubin
(mg/dL)
Days
to VOD
Response
Days
to VOD
Resolution
MOF Status Days at
Follow-
up
or Death
1 Pleuropulmonary
blastoma
Reversal of ﬂow
(26)
31 Steroids
(31)
4.8 4 8 Yes* Alive 1624
2 Chronic
granulomatous
disease
Reversal of ﬂow
(13)
12 Steroids
(14)
20.4 3 5 No Alive 1421
3 Retinoblastoma Reversal of ﬂow
(14)
14 Steroids
(15)
2.4 3 5 Yesy Alive 1270
4 ALL Reversal of ﬂow
(14)
13 Steroids and
deﬁbrotide
(14 and 16)
23.4 NR 38 Yes*,z Alive 766
5 Fanconi anemia Reversal of ﬂow
(23)
15 Steroids and
deﬁbrotide
(15 and 17)
24.7 NR N/A Yes* Dead
(adenovirus,
VOD, MOF)
150
6 Neuroblastoma Reversal of ﬂow
(13)
13 Steroids and
deﬁbrotide
(13 and 14)
4.6 5 5 Yes*,z Alive 382
7 Neuroblastoma Reversal of ﬂow
(11)
11 Steroids
(11)
1.3 6 6 Yes* Alive 183
8 ALL Reversal of ﬂow
(12)
12 Steroids
(12)
1.1 4 8 Yes* Alive 343
9 Dyskeratosis
congenita
Reversal of ﬂow (9) 5 Steroids and
deﬁbrotide
(5 and 9)
25.3 NR N/A Yes* Dead (VOD,
MOF)
59
BMT indicates bone marrow transplant; ALL, acute lymphoblastic leukemia; NR, nonresponder; N/A, not applicable; GVHD, graft versus host disease.
* Respiratory and renal failure.
y Respiratory failure.
z Hepatic encephalopathy.
K.C. Myers et al. / Biol Blood Marrow Transplant 19 (2013) 492e503502Although the pathophysiology is complex and remains
incompletely understood, antithrombotic and thrombolytic
agents have been evaluated for the treatment of VOD.
However, these approaches have been limited by signiﬁcant
toxicity, including fatal hemorrhages. Deﬁbrotide therapy is
available in United States on a compassionate-use basis,
needing an open institutional review boardeapproved
protocol, thus limiting availability in certain institutions.
Treatment with deﬁbrotide has reported response rates
between 24% and 55% [10]. In a recent cohort of patients with
severe VOD, a response rate of 28% was observed [11];
however, its use remains limited due to associated toxicities
and regulatory difﬁculties.
The pathogenesis of VOD is multifactorial and thought to
start with damage to hepatocytes and sinusoidal endothelial
cells secondary to the conditioning regimens associated with
HSCT. This damage results in endothelial activation initiating
a variety of downstream effects, including alterations in
proteins involved in the coagulation cascade as well as
cytokine activation [5,12,13]. Tissue damage from radiation
and chemotherapy may result in elevated levels of inﬂam-
matory cytokines, including interleukin-1, interleukin-2, and
tumor necrosis factor-alpha. Corticosteroids are potent
cytokine inhibitors and therefore may have a role in the
treatment of VOD.
An adult retrospective study by Khoury et al. [8] evaluated
liver regimenerelated toxicity response to early initiation of
high-dose steroids. Twenty-eight patients (20 with VOD and
8 with liver dysfunction of uncertain etiology [not meeting
Seattle criteria for bilirubin in VOD]) received the same high-
dose steroid regimen as described in our study (500 mg/m2
intravenous methylprednisolone every 12 hours for six
doses) with 61% response to therapy described as 50%
reduction in bilirubin at 10 days. None of the patients had
MOF at VOD diagnosis and initiation of steroid therapy, butsix nonresponders later developed organ failure that resulted
in their deaths [8]. However, in a subsequent report from the
same group, an additional 24 patients were treated, but with
only a 33% response rate [14]. Mortality among responders
(21%) was largely due to graft-versus-host disease or relapse,
whereas mortality among nonresponders (58%) was largely
due to organ failure and infection. Al Beihany et al. [15] also
prospectively evaluated the use of a lower dose steroid
regimen for longer duration (.5 mg/kg per dose intravenously
every 12 hours for 14 doses) in 48 patients diagnosed with
VOD after HSCT, with a 63% response rate and minimal
toxicity. Overall outcomes at 100 days post-HSCT in this
cohort were 58% among responders and 10% for nonre-
sponders. To date, there have been no reports of the use of
this therapeutic intervention in the pediatric HSCT pop-
ulation, although there are a few case reports using this
therapy successfully in the pediatric setting for VOD after
chemotherapy for solid tumors [16,17].
In our retrospective study we demonstrated therapy
response with complete resolution of VOD in 78% patients
receiving high-dose steroid therapy. All but one patient in
our cohort had VOD þ MOF when steroid therapy was
initiated. This is a very high response rate in comparisonwith
historical dismal outcomes reported in patients with VOD þ
MOF with acceptable steroid-related complications. Patients
who subsequently received deﬁbrotide therapy for severe
VOD were of comparable illness severity with patients
receiving only high-dose steroids because they were offered
deﬁbrotide based on institutional medication availability and
not due to selective clinical features. High-dose steroid
therapy was readily available and well tolerated. Prompt
initiation of steroid therapy before the evidence of reversal
portal ﬂow known to represent advanced liver injury likely
contributed to favorable disease outcomes even in patients
with MOF. In spite of comparable severity of MOF with those
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with MOF receiving steroids alone did well on this mono-
therapy, all responding and surviving their VOD. Life-
threatening therapy-related hemorrhagic complications
were observed in two patients receiving deﬁbrotide, neither
of whom survived. Our study is limited by its retrospective
nature, small numbers, and the confounding contribution of
the additional use of deﬁbrotide in same patients.
We conclude that high-dose steroid therapy if initiated
early may reverse severe VOD of the liver in pediatric HSCT
patients, abrogating the need for deﬁbrotide therapy with its
associated toxicities and regulatory difﬁculties. Steroid
therapy is readily available at any institution with known
expected side effects and standard monitoring. Further
prospective clinical trials are required to assess the true
efﬁcacy of high-dose steroid therapy for post-HSCT VOD.
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